Pimodivir

Pimodivir is an experimental antiviral drug developed by Janssen Pharmaceuticals. It is specifically designed to inhibit the replication of influenza A virus by targeting the viral protein PB2, a subunit of the influenza virus RNA polymerase complex.

Mechanism of Action

Pimodivir works by inhibiting the PB2 subunit of the influenza virus RNA polymerase complex. This complex is essential for the replication of the virus. By inhibiting PB2, Pimodivir prevents the virus from replicating within the host cell.

Clinical Trials

Pimodivir has undergone several clinical trials to evaluate its safety and efficacy. In Phase 2 trials, the drug was found to be well-tolerated and showed promising results in reducing the viral load in patients with influenza A. Phase 3 trials are currently underway.

Potential Use

If approved, Pimodivir could be used in the treatment of influenza A, particularly in cases where the virus has become resistant to other antiviral drugs. It could also potentially be used in combination with other antiviral drugs to enhance their effectiveness.

See Also

• Antiviral drug
• Influenza A virus
• Clinical trial
• Janssen Pharmaceuticals

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian